厄洛替尼治疗晚期非小细胞肺癌的疗效及安全性研究  

Clinical study on the clinical effects and safety of erlotinib in patients with advanced NSCLC

作　　者：张华勇[1] 吴烜[1] 李俏敏[1] 张斌[1] 韩强[1] 丁连举[1] 

机构地区：[1]中山大学附属第五医院,珠海519000

出　　处：《中国实用医药》2011年第6期24-26,共3页China Practical Medicine

摘　　要：目的厄洛替尼是治疗非小细胞肺癌的靶向药物,多项国内外研究已证明该药可延长非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的生存。本研究回顾性总结了厄洛替尼在非选择NSCLC人群中的应用,旨在探讨厄洛替尼治疗晚期非小细胞肺癌的远期疗效及安全性。方法回顾分析本院2006年3月至2009年7月之间接受化疗后应用厄洛替尼治疗化疗失败的晚期NSCLC患者,口服150 mg/d厄洛替尼直至疾病进展,观察疗效、生存时间和副反应。结果共有36例患者入组。36例患者中PR 22.2%(8/36),SD 50.0%(18/36),PD 27.8%(10/36),CR=O,DCR(CR+PR+SD)72.2%;PFS为5.8个月。其中腺癌与非腺癌、无吸烟者与吸烟者的疗效差异无统计学意义,但是生存曲线提示腺癌比非腺癌患者(7.6个月vs 1.0个月,P=0.037)、无吸烟比吸烟患者(11.1个月vs 4.6个月,P=0.025)具有更长的PFS,差异有统计学意义;性别因素未能影响疗效或PFS。毒副作用主要为为轻度皮疹、腹泻、转氨酶升高。结论厄洛替尼治疗晚期非小细胞肺癌有效,对腺癌和非吸烟人群有一定优势,且耐受性良好,是治疗晚期非小细胞肺癌患者的一个新的选择。Objective Erlotinib is one of the inhibitors of tyrosine kinase.Lots of clinical studies including home and abroad have proved thatit can prolong survival time in patients with NSCLC.The author retrospectively oberserved the response,survival and adverse reaction of erlotinib in non-selected non-small cell lung cancer in this study in order to analyze the clinical outcomes and safety in Erlotinib treated patients with advanced stage NSCLC.Methods A total of 36 patients who had received erlotinib therapy between Marck 2006 and July 2009 were retrospectively reviewed.The patients were given respectively Erlotinib（150 mg/d）untill disease progression.The clinical outcomes and adverse reactions were observed.Results 36 patients were inluded.The overall response rates（RR）,disease control rates（DCR）and Progression-free survival PFS were 22.2%,72.2%and 5.8 months respectively.Among these patients,the response between adenocarcinoma and non-adenocarcinoma or smoking and no-smoking patients had no statistically significant difference,but the median PFS was 7.6 months vs 1.0 months,11.1 months vs 4.6 months,both of which had statistically significant difference.There was no difference in response or suvival concerning the sexuality.The common toxic effects included skin rash,diarrhea,and elevated ALT.Conclusion Erlotinib has good effects in advanced NSCLC patients and is well tolerated in most patients.It seems to be much more effective in adenocarcinoma and non-smoking patients.It is a new choice for patients with advanced NSCLC.

关 键 词：非小细胞肺癌 厄洛替尼 安全性研究 

分 类 号：R734.2[医药卫生—肿瘤]